Does amoxicillin-clavulanate (Clavulin) interact with warfarin?

Yes, there is a clinically significant interaction between Clavulin (amoxicillin-clavulanate) and warfarin that can increase bleeding risk.

Clavulin can potentiate warfarin's anticoagulant effect, particularly at higher doses, leading to elevated INR values and increased bleeding risk. This interaction occurs through multiple mechanisms and requires proactive monitoring and management.

Mechanisms of Interaction

The interaction between amoxicillin-clavulanate and warfarin operates through several pathways 1:

• Gut microbiome disruption: All antibiotics, including amoxicillin-clavulanate, alter intestinal flora that produce vitamin K, thereby potentiating warfarin's anticoagulant effects 1
• Dose-dependent effect: The severity of interaction is directly related to the antibiotic dose administered

Clinical Evidence and Risk Magnitude

The dose of amoxicillin-clavulanate is critical to the interaction severity. In a prospective study of 120 patients, those receiving high-dose amoxicillin-clavulanate (10-12 g/day) had a significantly higher proportion of INR values ≥4 compared to those on usual doses (3.6 g/day): 87.5% versus 28.9% (P ≤ .001) 1, 2.

Case reports document severe consequences, including:

• INR elevation to 20.4 with life-threatening bleeding requiring fresh frozen plasma and vitamin K 3
• Marked hepatocellular injury (INR 7) when combined with warfarin in susceptible patients 4

However, a randomized controlled trial in 12 patients on stable warfarin therapy found no significant INR change with standard-dose amoxicillin-clavulanate in the absence of infection (mean INR increase 0.22 with antibiotic vs 0.24 with placebo, P=0.94) 5. This suggests the interaction may be more pronounced with higher doses or in the presence of acute illness.

Management Algorithm

When prescribing Clavulin to patients on warfarin:

1. Increase INR monitoring frequency 1:

   • Check INR within 3-5 days of starting the antibiotic
   • Recheck INR at completion of antibiotic course
   • Monitor for 1-2 weeks after antibiotic discontinuation

2. Consider dose-dependent risk 1:

   • Standard doses (≤3.6 g/day): Moderate risk—enhanced monitoring sufficient
   • High doses (10-12 g/day): High risk—consider empiric warfarin dose reduction or alternative antibiotic

3. Educate patients to watch for bleeding signs:

   • Unusual bruising, bleeding gums, blood in urine/stool
   • Instruct to seek immediate care if bleeding occurs

4. Document the interaction in the medical record and communicate with the anticoagulation management team if available

Important Caveats

• Polypharmacy amplifies risk: Each additional drug that increases INR raises the odds of INR ≥4 by 2.5-fold 2
• The FDA drug label explicitly lists penicillins (including amoxicillin-clavulanate) among drugs that may increase PT/INR response 6
• Infection itself may alter warfarin metabolism independent of antibiotic effects 7
• Individual variability exists—some patients show minimal interaction while others develop severe over-anticoagulation 3, 7

Alternative Considerations

If the infection permits and the patient is at high bleeding risk, consider antibiotics with lower warfarin interaction potential. However, amoxicillin-clavulanate remains a WHO AWaRe "Access" antibiotic and appropriate first-line choice for many infections when properly monitored 8.

The key is not to avoid the combination, but to anticipate the interaction and monitor accordingly. The interaction is manageable with appropriate INR surveillance, particularly when using standard antibiotic doses for short durations 7, 5.